Phase 2 Breast Cancer Trial, Not Yet Recruiting NCT05821686 Sponsor: Nova Scotia Health Authority Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Not Yet Recruiting

NCT05821686
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Women who have been diagnosed with triple-negative breast cancer (TNBC), confirmed by a biopsy, who are not planned to receive chemotherapy before surgery.
  • People whose breast tumor is 2 cm or smaller and has not spread to lymph nodes.
  • People who are planned to have surgery first, based on their own preference.
  • People who have a medical reason that means they are unable to receive chemotherapy before surgery.
  • People between 18 and 80 years of age.
  • People who are able to give their consent to take part in the study.
  • People who are able to travel to the hospital to receive injections directly into the tumor.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who do not have a diagnosis of triple-negative breast cancer (TNBC).
  • People who are not able to give their consent to take part in the study.
  • People who are not able to attend the hospital for study visits.
  • People who have a medical reason they cannot receive IL-2 therapy, such as an abnormal heart stress test, abnormal lung function test, a history of organ transplant, or previous serious side effects from IL-2 (confirm with trial site).
  • People who have previously experienced serious side effects from IL-2 treatment, including serious heart rhythm problems, chest pain, heart complications, severe kidney problems, severe breathing difficulties, prolonged loss of consciousness or confusion, seizures, bowel or serious digestive complications (confirm with trial site for the full list).
  • People who are currently taking other cancer treatment medications or steroids, due to the risk of drug interactions.
  • People who are known to be pregnant or breastfeeding, as there is not enough evidence on the safety of this treatment during pregnancy or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Nova Scotia Health Authority
Registry
ClinicalTrials.gov
Start date
2 January 2026
Est. completion
1 April 2028

Primary endpoints

Pathologic response as defined by the residual cancer burden (RCB) index (RCB 0-IV)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov